CSIMarket
 
Vaxcyte Inc   (PCVX)
Other Ticker:  
 
 
Price: $69.7000 $0.42 0.606%
Day's High: $69.82 Week Perf: -0.78 %
Day's Low: $ 67.69 30 Day Perf: -6.56 %
Volume (M): 1,465 52 Wk High: $ 82.04
Volume (M$): $ 102,104 52 Wk Avg: $53.23
Open: $68.71 52 Wk Low: $34.11



 Market Capitalization (Millions $) 7,086
 Shares Outstanding (Millions) 102
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -300
 Cash Flow (TTM) (Millions $) 267
 Capital Exp. (TTM) (Millions $) 14

Vaxcyte Inc
Vaxcyte Inc is a biotechnology company focused on developing innovative vaccines to prevent infectious diseases. The company utilizes its comprehensive understanding of bacterial pathogens and immunology to develop vaccines that address significant unmet medical needs. Vaxcyte aims to protect people of all ages, from infants to adults, against a range of infectious diseases. Their vaccines are designed to provide long-lasting protection, improve public health, and reduce the burden of infectious diseases globally. Vaxcyte is committed to advancing vaccine research and development to make a significant impact on global healthcare.


   Company Address: 825 Industrial Road San Carlos 94070 CA
   Company Phone Number: 837-0111   Stock Exchange / Ticker: NASDAQ PCVX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Vaxcyte's Phase 2 Study of VAX-24 Shows Promise for Prevention of Invasive Pneumococcal Disease in Infants with Broad Serotype Coverage

Published Mon, Mar 4 2024 1:30 PM UTC

Vaxcyte, a leading biotechnology company focused on developing innovative vaccines, has recently announced the completion of enrollment for its Phase 2 clinical study evaluating VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV), for the prevention of invasive pneumococcal disease (IPD) in infants. This significant milestone marks a major step forward in addressing a c...

Stock Market Announcement

Vaxcyte, Inc. Raises $862.5 Million in Record-Breaking Public Offering, Propelling Vaccine Innovator to New Heights

Published Fri, Feb 2 2024 11:39 PM UTC

Vaxcyte, Inc. Closes Highly Successful Public Offering, Raising $862.5 Million to Advance Breakthrough Vaccines
SAN CARLOS, Calif., Feb. 02, 2024 - Vaxcyte, Inc., a pioneering vaccine innovation company, has recently concluded its underwritten public offering, resulting in the successful issuance of over 12 million shares of common stock along with pre-funded warrants. T...

Shares

Vaxcyte Announces Pricing of Public Offering to Support Advances in Bacterial Disease Vaccines

Published Wed, Jan 31 2024 4:38 AM UTC


In a significant move towards advancing the fight against bacterial diseases, Vaxcyte, Inc. (Nasdaq: PCVX), a leading vaccine innovation company, has announced the pricing of its underwritten public offering of common stock and pre-funded warrants. The offering aims to raise approximately $750.0 million in gross proceeds, which will be crucial in furthering Vaxcyte's ef...

Financing Agreement

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Published Tue, Jan 30 2024 9:01 PM UTC

Vaxcyte, Inc., a clinical-stage vaccine innovation company specializing in high-fidelity vaccines against bacterial diseases, has recently announced the initiation of an underwritten public offering of its common stock and pre-funded warrants. With a mission to safeguard humanity from the consequences of bacterial diseases, Vaxcyte aims to raise capital through this offering...

Product Service News

Vaxcyte's Phase 1/2 Study of VAX-31 Advances Towards Addressing Invasive Pneumococcal Disease in Older Adults

Published Mon, Jan 29 2024 1:31 PM UTC

Vaxcyte, a leading biotechnology company focused on developing next-generation vaccines, recently announced the completion of enrollment for its Phase 1/2 study evaluating VAX-31 as a potential preventive measure for Invasive Pneumococcal Disease (IPD) in adults aged 50 and older. This milestone brings the company closer to its goal of addressing a significant public health ...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com